UC Berkeley researchers improve CRISPR-Cas9 gene editing technology 21 January 2016 | By Victoria White The researchers have announced a major improvement in CRISPR-Cas9 technology that achieves an unprecedented success rate of 60% when replacing a short stretch of DNA with another...
PDi launched to enhance translation of phenotypic biology to novel therapeutics 20 January 2016 | By Victoria White Through the Phenotypic Discovery Initiative (PDi), partners will build robust, disease-relevant phenotypic assays with a focus on human-derived systems with the aim of identifying new drug targets and hit molecules.
Microptosis could present an antimicrobial drug development opportunity 20 January 2016 | By Victoria White Researchers have described a novel pathway called microptosis where the immune system's killer cells deliver a 3-phase knockout punch that kills intracellular parasites...
Researchers freeze EBV by disrupting the cell supply chain 20 January 2016 | By Victoria White Researchers made B-cells sense they were starving by using the drug Rapamycin, enabling them to turn the senescence of EBV-infected cells on and off...
Regen BioPharma and NCATS to research the NR2F6 protein 20 January 2016 | By Victoria White The collaboration will focus on identifying ligands for NR2F6 using Regen's screening methodology and the expertise and unique chemical libraries of NCATS...
Mucosis secures €3.7m to advance its RSV vaccine, SynGEM 20 January 2016 | By Victoria White Mucosis has secured the €3.7 million translational fund award from the Wellcome Trust to progress SynGEM into Phase I and IIa human clinical trials...
New study finds laws of nature predict cancer evolution 19 January 2016 | By Victoria White Researchers believe that in the future, they could predict how a cancer will grow and develop by applying natural laws to single genetic snapshots taken from a cancer...
Time to renew the antibiotic arsenal 19 January 2016 | By Philippe Villain-Guillot, CEO, Nosopharm Philippe Villain-Guillot, CEO, Nosopharm, discusses antimicrobial resistance and the challenges facing antibacterial drug discovery and development...
Rapastinel demonstrates pro-cognitive benefits in animal model of cognitive impairment 19 January 2016 | By Victoria White Allergan has announced new data on the investigational medication rapastinel (GLYX-13) and its lack of impairment on cognitive function...
Breast cancer study reveals new drug targets and combinations 19 January 2016 | By Victoria White The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations...
UCL announces new £50 million fund to commercialise research 18 January 2016 | By Victoria White The Fund will be used to support academics whose research has commercial potential, with funding for early stage proof of concept, licensing projects and new spinout companies...
F-star and AbbVie to develop bispecific antibodies in immuno-oncology 18 January 2016 | By Victoria White Under the collaboration agreement, F-star and AbbVie will create Fcabs against two immuno-oncology targets and generate several mAb2 drug development candidates from these Fcabs...
Centauri acquires Alphamer technology from Altermune 18 January 2016 | By Victoria White Centuari has also announced that it has appointed Dr Clive Dix as Chairman and secured the first tranche of a £3M raise to develop its first lead candidate...
Channel-blocker drug helps restore vision in mice with optic nerve injury 14 January 2016 | By Victoria White Researchers were able to restore vision in mice by using gene therapy to get the nerves to regenerate and adding a channel-blocking drug to help the nerves conduct impulses...
Calibr and Pfizer to develop heart failure therapies 14 January 2016 | By Victoria White Calibr's antibody fusion technology provides a proprietary, modular approach to developing long-acting biotherapeutics based on peptide and protein agonists and antagonists...
